One-way sensitivity analysis. One-way sensitivity analysis for the utility of the state “No relapse with GVHD” after allogeneic transplantation in CR1 among patients with intermediate-risk AML is shown. The green dot represents the QOL-adjusted life expectancy when allo-HCT was performed in CR1. The blue dot represents the QOL-adjusted life expectancy when treated with chemotherapy in CR1. The median value of the utility for this state provided by physicians was 0.60, shown as a red star. At the median value, QOL-adjusted life expectancy in the HCT group is shown to outweigh that in the CTx group. The threshold value at which the favored decision is altered was 0.44, shown as a black dotted line. The plausible range of the utility provided by physicians was 0.40-0.80, shown as a red transparent square. Because the threshold value, 0.44, was included within the plausible range, this sensitivity analysis indicates that this result favoring HCT may be altered, depending on how the QOL of chronic GVHD is evaluated. Such results that favored a decision may change within the plausible range are interpreted as “sensitive.” If the plausible range was provided in 0.50-0.80, this result would turn to “not sensitive,” indicating that the favored decision does not change. QOL indicates quality of life; CR1, first complete remission; HCT, allogeneic hematopoietic cell transplantation; CTx, chemotherapy; and GVHD, graft-versus-host disease.